ALT
Altimmune, Inc.
$2.87
+0.02
(+0.70%)
Mkt Cap
253.30M
Volume
2,962,450
52W Range
2.56-6.44
Sector
Healthcare
Beta
0.24
EPS (TTM)
-0.93
P/E Ratio
-3.61
Revenue (TTM)
36,000
Rev Growth (5Y)
-65.3%
EPS Growth (5Y)
N/A
Company Description
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 41,000 | 20,000 | 426,000 | (68,000) | 4.41M | 8.19M | 5.80M | 10.33M | 41,503 | 5.23M | 10.64M | 10.19M |
| Net Income | (88.09M) | (95.06M) | (88.45M) | (84.71M) | (97.09M) | (49.04M) | (20.52M) | (39.17M) | (46.43M) | 193.85M | (3.44M) | (9.96M) |
| EPS | -1.00 | -1.34 | -1.66 | -1.81 | -2.35 | -1.91 | -1.56 | -13.98 | -108.77 | -49.80 | -16.13 | -51.91 |
| Free Cash Flow | (67.55M) | (79.85M) | (75.86M) | (62.71M) | (90.55M) | (34.65M) | (9.60M) | (10.40M) | (20.38M) | 201.48M | (3.30M) | (8.57M) |
| FCF / Share | -0.77 | -1.12 | -1.42 | -1.34 | -2.19 | -1.35 | -0.73 | -3.71 | -47.75 | 874.54 | -15.48 | -44.67 |
| Operating CF | (67.53M) | (79.85M) | (75.81M) | (62.59M) | (78.24M) | (34.31M) | (9.60M) | (9.39M) | (20.21M) | 201.51M | (3.22M) | (8.47M) |
| Total Assets | 279.93M | 139.31M | 210.64M | 206.93M | 218.87M | 245.12M | 54.06M | 54.75M | 63.03M | 224.74M | 19.86M | 21.98M |
| Total Debt | 35.69M | 1.68M | 671,000 | 1.12M | 1.53M | 1.82M | 1.74M | 572,770 | 49,702 | 984,580 | 1.08M | 746,146 |
| Cash & Equiv | 43.76M | 36.93M | 135.12M | 111.10M | 190.30M | 115.92M | 8.96M | 33.72M | 8.77M | 153.99M | 15.57M | 18.64M |
| Book Value | 224.89M | 123.51M | 194.10M | 185.29M | 199.13M | 225.88M | 45.52M | 48.31M | 48.68M | 19.46M | 16.65M | 18.27M |
| Return on Equity | -0.39 | -0.77 | -0.46 | -0.46 | -0.49 | -0.22 | -0.45 | -0.81 | -0.95 | 9.96 | -0.21 | -0.54 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 26,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 37,000 | 362,000 | 6,000 |
| Net Income | (22.56M) | (27.36M) | (19.01M) | (22.15M) | (19.57M) | (23.18M) | (22.84M) | (24.64M) | (24.39M) | (31.64M) | (20.67M) | (16.06M) |
| EPS | -0.18 | -0.27 | -0.21 | -0.27 | -0.26 | -0.33 | -0.32 | -0.35 | -0.34 | -0.54 | -0.39 | -0.32 |
| Free Cash Flow | (20.96M) | (19.45M) | (11.90M) | (19.36M) | (16.84M) | (18.27M) | (27.12M) | (18.11M) | (16.36M) | (16.53M) | (20.49M) | (19.56M) |
| FCF / Share | -0.17 | -0.19 | -0.13 | -0.24 | -0.22 | -0.26 | -0.38 | -0.26 | -0.23 | -0.28 | -0.38 | -0.39 |
| Operating CF | (20.94M) | (19.45M) | (11.90M) | (19.35M) | (16.84M) | (18.27M) | (27.12M) | (18.11M) | (16.36M) | (16.53M) | (20.49M) | (19.57M) |
| Total Assets | 335.63M | 279.93M | 218.45M | 190.35M | 157.26M | 139.31M | 147.86M | 173.35M | 188.36M | 210.64M | 166.57M | 183.32M |
| Total Debt | 35.85M | 35.69M | 15.90M | 15.85M | 1.59M | 1.68M | 1.77M | 1.86M | 552,000 | 671,000 | 788,000 | 903,000 |
| Cash & Equiv | 97.60M | 43.76M | 61.24M | 183.10M | 49.10M | 36.93M | 31.47M | 57.13M | 78.98M | 135.12M | 86.86M | 102.35M |
| Book Value | 283.99M | 224.89M | 185.60M | 161.37M | 142.16M | 123.51M | 133.38M | 152.53M | 172.94M | 194.10M | 150.40M | 167.71M |
| Return on Equity | -0.08 | -0.12 | -0.10 | -0.14 | -0.14 | -0.19 | -0.17 | -0.16 | -0.14 | -0.16 | -0.14 | -0.10 |
ALT News
Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - Upgrade
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report?
Altimmune, Inc. (ALT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Altimmune Sets Pemvidutide's Phase 3 MASH Playbook as AUD Data Near
ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup
ALT and the Rise of Dual Agonists Targeting Liver Disease
Is Altimmune Worth Buying Ahead of 2026 Catalysts?